XETRA - Delayed Quote • EUR Reckitt Benckiser Group plc (3RB.DE) Follow Compare 59.12 +0.80 +(1.37%) At close: 5:35:34 PM GMT+1 All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Reckitt to Boost US, China Production as Tariff Risks Loom (Bloomberg) -- Reckitt Benckiser Plc is ramping up manufacturing in the US and China to bolster its supply chain and potentially lessen its exposure to fresh trade wars.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC, Some Call for More RegulationsChicago Agency Pitches $1.5 Billion Plan to Fix Transit WoesNYPD Reforms Car Chase Policy Amid Rising Crashes, InjuriesChurches, Cinemas — and Moon Artifacts — Top List of Endangered MonumentsThe Best paying FTSE 100 stocks of 2024 London-listed firms that have served investors well delivering high yields. Reckitt bolsters US presence with new Wilson OTC facility The new facility will help to boost Reckitt's production of Mucinex cold and flu relief to meet increased demand in the US. Returns On Capital Are Showing Encouraging Signs At Reckitt Benckiser Group (LON:RKT) What are the early trends we should look for to identify a stock that could multiply in value over the long term... Reckitt Prescribes More U.S. Production for Drug Supply Chain The company is establishing a North Carolina factory for cold medicine as postpandemic pharma demand has grown more unpredictable. Should We Be Delighted With Reckitt Benckiser Group plc's (LON:RKT) ROE Of 19%? While some investors are already well versed in financial metrics (hat tip), this article is for those who would like... Bernstein downgrades Reckitt; litigation rollercoaster continues Bernstein downgraded its investment stance on Reckitt Benckiser (LON:RKT), citing the continuation of a rollercoaster of litigation which has hit the consumer goods giant hard. At 08:15 ET (13:15 GMT), Reckitt stock fell 0.4% to £49.75, having fallen over 8% over the course of the year. “Reckitt shares have suffered from a rollercoaster over the past twelve months, driven in no small part by the NEC litigation in the US,” said analysts at Bernstein, in a note dated Nov. 4. Abbott, Reckitt found not liable in baby formula case. Stocks rise. A Missouri jury found Abbott Laboratories (ABT) and a unit of Reckitt Benckiser (RBGLY) not responsible for an infant death originally claimed to be tied to the company's baby formulas. The two health companies are seeing their shares rise on Friday following this legal victory. Market Domination's Julie Hyman and Josh Lipton report more on the story. To watch more expert insights and analysis on the latest market action, check out more Market Domination here. This post was written by Luke Carberry Mogan. Reckitt’s Mead Johnson, Abbott cleared by US court in infant-formula case The Whitfield family legal case was just one of many still pending relating to the necrotizing enterocolitis (NEC) disease. Abbott, Reckitt Stocks Gain as Baby Formula Makers Score Rare Legal Win Shares of Abbott Laboratories are rising and those of Reckitt Benckiser are gaining in London trading Friday, a day after a Missouri jury cleared the two infant formula makers of liability for a boy's debilitating intestinal disease. Abbott, Reckitt Stocks Rise on Baby-Formula Lawsuit Win Shares of Abbott Laboratories and Reckitt Benckiser rose after the companies won a victory in litigation over the safety of some baby-formula products. Abbott shares rose 4% in early New York trading, while Reckitt’s shares were up 8% in London. A jury in Missouri state court found Reckitt’s Mead Johnson unit and Abbott weren't liable for injuries suffered by a boy who consumed their formulas designed for premature babies, following a civil trial. Friday's FTSE 100 risers and fallers: Tesco, Frasers and EasyJet Investor updates on the companies trending on the UK blue-chip index on Friday. Abbott shares rise after securing first win in premature infant formula trial A jury in St. Louis, Missouri found on Thursday that Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's severe intestinal disease, marking the first victory for the companies after large losses in two previous trials. The lawsuit was one of about 1,000 similar cases pending nationwide over allegations the companies failed to warn that their specialized formulas used by newborn intensive care units in hospitals could cause necrotizing enterocolitis (NEC). NEC almost exclusively affects premature infants and has an estimated mortality rate of more than 20%. Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win Shares in Reckitt Benckiser topped the Stoxx Europe 600 Index after a U.S. court cleared the company of liability in a case concerning its baby formulas. Reckitt, Abbott surge after winning an NEC case Investing.com -- A jury ruled on Thursday that Abbott Laboratories (NYSE:ABT) and Mead Johnson, a division of Reckitt Benckiser (LON:RKT), are not liable for a young boy's severe intestinal disease, marking a significant win for the companies after substantial losses in similar cases. Jury asked to award more than $6 billion in preterm formula case against Abbott, Reckitt's Mead (Reuters) -A lawyer for a Missouri mother on Wednesday asked a jury to make Abbott and Reckitt's Mead Johnson pay a total of more than $6 billion in the latest trial over claims that the companies' formulas for premature babies caused a severe intestinal illness. Abbott CEO Robert Ford has told investors that it may pull its premature infant formula from the market because of the litigation. Reckitt in July said it was "considering options" for Mead Johnson, and CEO Kris Licht did not rule out a sale. Reckitt sees sales of new hyaluronic acid condoms surge in China Reckitt launched its first hyaluronic acid-lubricated Durex condoms across China in October 2022. The past five-year earnings decline for Reckitt Benckiser Group (LON:RKT) likely explains shareholders long-term losses While not a mind-blowing move, it is good to see that the Reckitt Benckiser Group plc ( LON:RKT ) share price has... Tesla profits jump amid rebound in demand for electric cars Elon Musk’s Tesla has revealed an unexpected rise in profits in a sign of rebounding demand for electric cars. RBGLY or CLX: Which Is the Better Value Stock Right Now? RBGLY vs. CLX: Which Stock Is the Better Value Option? Performance Overview Trailing total returns as of 1/17/2025, which may include dividends or other distributions. Benchmark is FTSE 100 Return 3RB.DE FTSE 100 YTD +1.51% +4.73% 1-Year -6.31% +12.53% 3-Year -13.74% +12.76%